Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Offering SPR-BLI Services - Proteins provided for free!
Thank you for choosing ACROBiosystems. Would you rate our product and service? Thank you for choosing ACROBiosystems. Would you rate our product and service?
Here come GMP Grade Cytokines!Free Sample is available! Here come GMP Grade Cytokines!Free Sample is available!
製造番号 | 種類 | 製品説明 | 構造 | 純度 | 特徴 |
---|---|---|---|---|---|
GA3-H5247 | Human | Human Galectin-3 Protein, His Tag |
|
||
GA3-H5129 | Human | Human Galectin-3 Protein, His Tag (MALS verified) |
|
The purity of Human Galectin-3, His Tag (Cat. No. GA3-H5129) is more than 90% and the molecular weight of this protein is around 23-35 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Ocriplasmin | A-01016; THR-409 | Approved | Thrombogenics | Jetrea, Jejetrea | United States | Vitreomacular Adhesion | Thrombogenics Inc | 2012-10-17 | Vitreous Detachment; Arterial Occlusive Diseases; Disease Progression; Stroke; Retinal Diseases; Diabetic macular oedema; Uveitis; Vitreomacular Adhesion; Venous Thrombosis; Eye Diseases; Macular Degeneration; Diabetic Retinopathy; Retinal Vein Occlusion | Details |
Ocriplasmin | A-01016; THR-409 | Approved | Thrombogenics | Jetrea, Jejetrea | United States | Vitreomacular Adhesion | Thrombogenics Inc | 2012-10-17 | Vitreous Detachment; Arterial Occlusive Diseases; Disease Progression; Stroke; Retinal Diseases; Diabetic macular oedema; Uveitis; Vitreomacular Adhesion; Venous Thrombosis; Eye Diseases; Macular Degeneration; Diabetic Retinopathy; Retinal Vein Occlusion | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Belapectin | GR-MD-02 | Phase 3 Clinical | Galectin Therapeutics Inc | Metabolic Dysfunction-Associated Steatotic Liver Disease; Squamous Cell Carcinoma of Head and Neck; Fibrosis; Hypertension, Portal; Psoriasis; Hepatic Insufficiency; Esophageal and Gastric Varices; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
ProLectin-M | Phase 3 Clinical | BioXyTran Inc | Cytokine Release Syndrome; Coronavirus Disease 2019 (COVID-19); Influenza, Human | Details | |
Olitigaltin | GB-0139; TD-139 | Phase 2 Clinical | The University Of Edinburgh, Lund University Foundation | Idiopathic Pulmonary Fibrosis; Coronavirus Disease 2019 (COVID-19) | Details |
Galactomannan C | GM-CT-01 | Phase 2 Clinical | Galectin Therapeutics Inc | Head and Neck Neoplasms; Coronavirus Disease 2019 (COVID-19); Small Cell Lung Carcinoma; Breast Neoplasms; Prostatic Neoplasms; Coronaviridae Infections; Colorectal Neoplasms; Bile Duct Neoplasms; Lung Neoplasms; Gallbladder Neoplasms; Melanoma | Details |
Selvigaltin | GB-1211; GB1211 | Phase 2 Clinical | Galecto Inc | Squamous Cell Carcinoma of Head and Neck; Metabolic Dysfunction-Associated Steatotic Liver Disease; Hepatic Insufficiency; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
Gal-400 | Gal-400 | Phase 1 Clinical | Galecto Inc | Metabolic Dysfunction-Associated Steatotic Liver Disease; Liver Cirrhosis | Details |
Belapectin | GR-MD-02 | Phase 3 Clinical | Galectin Therapeutics Inc | Metabolic Dysfunction-Associated Steatotic Liver Disease; Squamous Cell Carcinoma of Head and Neck; Fibrosis; Hypertension, Portal; Psoriasis; Hepatic Insufficiency; Esophageal and Gastric Varices; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
ProLectin-M | Phase 3 Clinical | BioXyTran Inc | Cytokine Release Syndrome; Coronavirus Disease 2019 (COVID-19); Influenza, Human | Details | |
Olitigaltin | GB-0139; TD-139 | Phase 2 Clinical | The University Of Edinburgh, Lund University Foundation | Idiopathic Pulmonary Fibrosis; Coronavirus Disease 2019 (COVID-19) | Details |
Galactomannan C | GM-CT-01 | Phase 2 Clinical | Galectin Therapeutics Inc | Head and Neck Neoplasms; Coronavirus Disease 2019 (COVID-19); Small Cell Lung Carcinoma; Breast Neoplasms; Prostatic Neoplasms; Coronaviridae Infections; Colorectal Neoplasms; Bile Duct Neoplasms; Lung Neoplasms; Gallbladder Neoplasms; Melanoma | Details |
Selvigaltin | GB-1211; GB1211 | Phase 2 Clinical | Galecto Inc | Squamous Cell Carcinoma of Head and Neck; Metabolic Dysfunction-Associated Steatotic Liver Disease; Hepatic Insufficiency; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
Gal-400 | Gal-400 | Phase 1 Clinical | Galecto Inc | Metabolic Dysfunction-Associated Steatotic Liver Disease; Liver Cirrhosis | Details |
This web search service is supported by Google Inc.